Tvardi Therapeutics, Inc. (TVRD)
Market Cap | 252.07M |
Revenue (ttm) | n/a |
Net Income (ttm) | -23.63M |
Shares Out | 9.38M |
EPS (ttm) | -3.94 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 16,604 |
Open | 25.79 |
Previous Close | 24.67 |
Day's Range | 25.22 - 27.25 |
52-Week Range | 8.13 - 34.31 |
Beta | n/a |
Analysts | Strong Buy |
Price Target | 59.20 (+120.24%) |
Earnings Date | Aug 14, 2025 |
About TVRD
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in pre-clinical stage.... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for TVRD stock is "Strong Buy." The 12-month stock price target is $59.2, which is an increase of 120.24% from the latest price.
News

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Newly public Tvardi Therapeutics, Inc. TVRD is capturing investor attention following its recent reverse merger with Cara Therapeutics, Inc.

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

Tvardi Therapeutics to Participate in Upcoming Investor Conferences
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical- stage biopharmaceutical company focused on the development of novel, oral, sma...

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference
HOUSTON--(BUSINESS WIRE)-- #IdiopathicPulmonaryFibrosis--Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, smal...

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics
Merger creates a Nasdaq-listed, clinical-stage biopharmaceutical company – Tvardi Therapeutics – developing novel treatments targeting STAT3 to treat fibrosis-driven diseases.